Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA

@inproceedings{Qin2015InhibitingNF,
  title={Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA},
  author={Jiang-jiang Qin and Wei Wang and Sukesh Voruganti and Hui Min Wang and W. M. Zhang and Ruiwen Zhang},
  booktitle={Oncotarget},
  year={2015}
}
Transcription factor NFAT1 has been recently identified as a new regulator of the MDM2 oncogene. Targeting the NFAT1-MDM2 pathway represents a novel approach to cancer therapy. We have recently identified a natural product MDM2 inhibitor, termed JapA. As a specific and potent MDM2 inhibitor, JapA inhibits MDM2 at transcriptional and post-translational… CONTINUE READING